Tropical Journal of Pharmaceutical Research

Original Research Article | OPEN ACCESS

Effect of combination of parenteral edaravone and nimodipine on ischemic cerebral injury following cerebral hemorrhage

Qiuju Li¹, Zhiling Ji², Kun Li³

¹Department of Rehabilitation, Jining No. 1 People's Hospital, Jining City; ²Department of Neurology, Weifang Yidu Central Hospital, Weifang City; ³Department of Emergency, Jining No. 1 People's Hospital, Jining City, Shandong Province, China.

For correspondence:- Kun Li Email: kt0749@163.com

Accepted: 27 April 2018 Published: 28 May 2018

Citation: Li Q, Ji Z, Li K. Effect of combination of parenteral edaravone and nimodipine on ischemic cerebral injury following cerebral hemorrhage. Trop J Pharm Res 2018; 17(5):955-960 doi: 10.4314/tjpr.v17i5.27

© 2018 The authors.
This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/read), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited..

Abstract

Purpose: To study the clinical effects of parenteral edaravone when combined with nimodipine for the treatment of ischemic cerebral injury following cerebral hemorrhage, and its influence on D-dimer, brain natriuretic peptide (BNP) and transcription factor kB (NF-kB) levels.

Methods: A total of 102 cases of ischemic cerebral injury after cerebral hemorrhage seen in 215 Hospital of Nuclear Industry in Shanxi, China from January, 2016 to January, 2017 were included in this study. They were randomly divided into two groups, viz, fifty-two cases in control group and fifty cases in observation group. Control group received nimodipine, while the observation group was given edaravone. Before and after treatment, the two groups’ NIHSS scores were compared. Adverse reactions were recorded, and clinical effectiveness was evaluated. Enzyme-linked immunosorbent assay (ELISA) was used to determin thee levels of serum D-dimmer, BNP and NF-kB in the two groups.

Results: Before treatment, the two groups’ NIHSS scores did not show significant differences (p > 0.05). However, after treatment, the observation group’s NIHSS score was significantly lower than that of the control group (p < 0.05). Total effectiveness in the observation and control groups were 98.0 and 80.8 %, respectively. Clinical effectiveness in patients in the observation group was significantly better than that of the control group (p < 0.05). Before treatment, D-dimmer, BNP and NF-kB levels of patients in the two groups showed no significant difference (p > 0.05). However, compared with the control group, D-dimmer, BNP and NF-kB levels in the observation group post-treatment decreased significantly (p < 0.05).

Conclusion: These results suggest that the combination of parenteral edaravone and nimodipine has relatively high efficiency and safety, mitigates cerebral ischemia and cerebral edema, and controls inflammatory reactions. Thus, its potentials in this regard requires further investigation.

Keywords: Edaravone, Nimodipine, Cerebral ischemia, Ischemic cerebral injury